Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | PDE4A | P27815 | 1/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17479352 | 1.00 | ALDH1A1 (0.76) | ALDH1A1KMT2ALMNAMEN1PDE4A | |
| SCHEMBL28257095 | 0.93 | ALDH1A1 (0.74) | ALDH1A1KMT2ALMNAPDE4APDE4B | |
| SCHEMBL19230174 | 0.88 | ALDH1A1 (0.70) | ALDH1A1KMT2ALMNAMEN1GAA | |
| SCHEMBL1710961 | 0.86 | ALDH1A1 (1.00) | ALDH1A1KMT2ALMNAMEN1GAA | |
| SCHEMBL17479215 | 0.85 | ALDH1A1 (0.78) | ALDH1A1KMT2ALMNAMEN1SMN1; SMN2 | |
| SCHEMBL925723 | 0.85 | ALDH1A1 (0.78) | ALDH1A1KMT2ALMNAMEN1SMN1; SMN2 | |
| SCHEMBL15899792 | 0.84 | ALDH1A1 (0.76) | ALDH1A1KMT2ALMNAMEN1PDE4A | |
| SCHEMBL15575103 | 0.83 | ALDH1A1 (0.75) | ALDH1A1KMT2ALMNAMEN1SMN1; SMN2 | |
| SCHEMBL15575170 | 0.82 | ALDH1A1 (0.73) | ALDH1A1KMT2ALMNAMEN1PDE4A | |
| SCHEMBL26145014 | 0.82 | ALDH1A1 (0.55) | ALDH1A1KMT2ALMNAGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107001283-B | FLT3 receptor antagonists | 国家健康与医学研究院 | 2021-05-25 | — | — | CN | disclosed |
| EP-3174859-B1 | FLT3 RECEPTOR ANTAGONISTS | INST NAT SANTE RECH MED (FR) | 2020-04-29 | — | — | EP | disclosed |
| US-10065937-B2 | FLT3 receptor antagonists | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2018-09-04 | — | — | US | disclosed |
| US-20170233354-A1 | FLT3 RECEPTOR ANTAGONISTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-08-17 | — | — | US | disclosed |
| EP-3174859-A1 | FLT3 RECEPTOR ANTAGONISTS | INSERM - Institut National de la Santé et de la Recherche Médicale (FR) | 2017-06-07 | — | — | EP | disclosed |
| WO-2016016370-A1 | FLT3 RECEPTOR ANTAGONISTS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233354-A1 | FLT3 RECEPTOR ANTAGONISTS | FLT3, CSF1R, CSF3R | ALDH1A1 2419/4885KMT2A 1531/4885LMNA 4733/4885 |
| US-10065937-B2 | FLT3 receptor antagonists | FLT3, CSF1R, CSF3R | ALDH1A1 2419/4885KMT2A 1531/4885LMNA 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.